Metabonomics and Molecular Biology-based Effects of Sugemule-3 in an Isoproterenol-induced Cardiovascular Disease Rat Model
Cardiovascular disease(CVD) is a common and serious disease in the elderly, which has characteristically high prevalence, disability, and mortality rates. However, the etiology of CVD is still not very clear. The traditional Mongolian medicine Sugemule-3(SM) is usually used for the treatment of CVD and exhibits a good curative effect. In this study, a serum metabolite profile analysis was used to identify potential biomarkers associated with isoproterenol(ISO)-induced CVD and investigate the mechanism of the action of SM. Ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry(UPLC-Q-TOF-MS) was used for the metabonomics analysis. Principal component analysis(PCA) was used to process the acquired data to differentiate the results of the control, CVD, and SM treatment groups. Orthogonal partial least squares discriminant analysis(OPLS-DA) enabled the identification of 21 metabolites as potential biomarkers that were relevant to phospholipid and energy metabolism. The results indicate that SM played a protective role against ISO-induced CVD in rats by regulating phospholipid and energy metabolic pathways. Further, we verified the apoptotic metabolic pathway using molecular biology methods, such as terminal deoxynucleotidyl transferase(TdT) deoxyuridine 5′-triphosphate(dUTP) nick-end labeling(TUNEL) assay and Western blot analysis. Furthermore, this study identified early biomarkers of CVD and elucidated the underlying mechanism of the therapeutic actions of SM, which is worth further to be investigated for development as a clinical therapy.
KeywordsSugemule-3 Metabonomics Molecular biology Ultra-performance liquid chromatography coupled with mass spectrometry(UPLC-MS) Cardiovascular disease Isoproterenol
Unable to display preview. Download preview PDF.
- Esposito K., Giugliano D., N. Engl. J. Med., 2013, 369, 674Google Scholar
- Chang Y., Zhang P., Zhang X., Nat. Prod. Res., 2016, 12, 1Google Scholar
- Nimaradan U., Four Medical Tantras, 2nd Ed., People’s Medical Publishing House, Beijing, 1983Google Scholar
- Wang Y., Gong G. H., Xu Y. N., Yu L. J., Wei C. X., Pharmacognosy Magazine, 2017, 51, 517Google Scholar
- Zhao Y. Y., Lei P., Chen D. Q., Feng Y. L., Bai X., J. Pharm. Biomed. Anal., 2013, 81, 202Google Scholar
- Wang X. Y., Shan X. T., Wang Y. L., Li D., Zhao M., Xu L., Chem. J. Chinese Universities, 2016, 37(5), 844Google Scholar
- Li P. H., Deng L. L., Luo J., Li W., Ning J., Ding J. H., Wu X. P., Chem. J. Chinese Universities, 2016, 37(4), 626Google Scholar
- Zhang R. X., Liu S., Pi Z. F., Song F. R., Liu Z. Q., Chem. J. Chinese Universities, 2014, 35(6), 1146Google Scholar
- Kikkawa U., Takai Y., Minakuchi R., Inohara S., Nishizuka Y., J. Biol. Chem., 1982, 257, 13341Google Scholar
- Sklyarov A.Y., Panasyuk N. B., Fomenko I. S., J. Physiol. Pharma-col., 2011, 62, 65Google Scholar